Equities Analysts Issue Forecasts for TSE:FRX Q4 Earnings

Fennec Pharmaceuticals Inc. (TSE:FRX) – Equities researchers at Wedbush raised their Q4 2024 earnings per share estimates for Fennec Pharmaceuticals in a note issued to investors on Sunday, December 22nd. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will earn $1.88 per share for the quarter, up from their previous forecast of ($0.24). The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.60 per share. Wedbush also issued estimates for Fennec Pharmaceuticals’ Q1 2025 earnings at ($0.20) EPS, Q2 2025 earnings at ($0.16) EPS, Q4 2025 earnings at $0.66 EPS and FY2025 earnings at $0.66 EPS.

Separately, Stephens raised shares of Fennec Pharmaceuticals to a “strong-buy” rating in a report on Monday, November 18th.

Fennec Pharmaceuticals Trading Up 0.2 %

FRX stock opened at C$8.93 on Wednesday. The stock has a market cap of C$244.32 million, a price-to-earnings ratio of 89.30 and a beta of 0.25. The company has a fifty day moving average price of C$7.30 and a two-hundred day moving average price of C$7.66. Fennec Pharmaceuticals has a one year low of C$5.65 and a one year high of C$15.43. The company has a debt-to-equity ratio of 1,040.68, a current ratio of 8.02 and a quick ratio of 10.17.

Insider Buying and Selling

In other news, Senior Officer Robert Christopher Andrade acquired 15,816 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The shares were acquired at an average cost of C$3.43 per share, with a total value of C$54,248.88. Also, Director Rostislav Christov Raykov acquired 25,000 shares of the stock in a transaction on Friday, December 20th. The shares were purchased at an average price of C$3.87 per share, with a total value of C$96,840.00. Over the last three months, insiders have acquired 41,612 shares of company stock valued at $157,868. 16.20% of the stock is owned by company insiders.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.